

DAFTAR PUSTAKA

- Abramowicz, J. S., & Timmerman, D. (2017). Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. *American journal of obstetrics and gynecology*, 217(6), 652–660. <https://doi.org/10.1016/j.ajog.2017.07.019>
- Adami H-O, Lambe M, Persson I, et al. (1994). Parity, age at first childbirth, and risk of ovarian cancer. *Lancet*;344 (8932):1250–1254. doi:10.1016/S0140-6736(94)90749-8
- Akter, S., Rahman, M. A., Hasan, M. N., Akhter, H., Noor, P., Islam, R., Shin, Y., Rahman, M. D. H., Gazi, M. S., Huda, M. N., Nam, N. M., Chung, J., Han, S., Kim, B., Kang, I., Ha, J., Choe, W., Choi, T. G., & Kim, S. S. (2022). Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. *Cells*, 11(4), 650. <https://doi.org/10.3390/cells11040650>
- Ali AT. Towards prevention of ovarian cancer. *Curr Cancer Drug Targets*. 2018;18(6):522–537. doi:10.2174/1568009618666180102103008.
- Ali AT. Can we prevent ovarian cancer? *Ceska Gynekol*. 2020;85(1):49–58. Ali AT. Reproductive factors and the risk of ovarian cancer. *Int J Gynecol Cancer*. 2020;30(6):807–812.
- Ali, A. T., Al-Ani, O., & Al-Ani, F. (2023). Epidemiology and risk factors for ovarian cancer. *Przegląd menopauzalny = Menopause review*, 22(2), 93–104. <https://doi.org/10.5114/pm.2023.128661>
- Allensworth, S., Langstraat, C., Martin, J., Lemens, M., McGree, M., Weaver, A., ... & Bakkum-Gamez, J. (2013). Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. *Gynecologic Oncology*, 130(3), 499-504. <https://doi.org/10.1016/j.ygyno.2013.05.038>
- Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. *Obstet Gynecol*. 2006;107(1):77–85.
- Anderson JP, Ross JA, Folsom AR. (2004). Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women's Health Study. *Cancer*;100(7):1515–1521. doi:10.1002/cncr.20146
- Andreou, Maria, Maria Kyprianidou, Christos Cortas, Irene Polycarpou, Demetris Papamichael, Panteleimon Kountourakis, and Konstantinos Giannakou. (2023). Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study. *Cancers* 15, no. 24: 5710. <https://doi.org/10.3390/cancers15245710>
- Araujo, K. G., Jales, R. M., Pereira, P. N., Yoshida, A., de Angelo Andrade, L., Sarian, L. O., & Derchain, S. (2017). Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 49(6), 778–783. <https://doi.org/10.1002/uog.15963>

- Azoulay, D., Eshkenazy, R., Pery, R., Cordoba, M., Haviv, Y., Inbar, Y., ... & Lim, C. (2021). The Impact of Establishing a Dedicated Liver Surgery Program at a University-affiliated Hospital on Workforce, Workload, Surgical Outcomes, and Trainee Surgical Autonomy and Academic Output. *Annals of Surgery Open*, 2(2), e066. <https://doi.org/10.1097/as9.0000000000000066>
- Babaier, A., Mal, H., Alselwi, W., & Ghatage, P. (2022). Low-Grade Serous Carcinoma of the Ovary: The Current Status. *Diagnostics (Basel, Switzerland)*, 12(2), 458. <https://doi.org/10.3390/diagnostics12020458>
- Babic, A., Sasamoto, N., Rosner, B. A., Tworoger, S. S., Jordan, S. J., Risch, H. A., Harris, H. R., Rossing, M. A., Doherty, J. A., Fortner, R. T., Chang-Claude, J., Goodman, M. T., Thompson, P. J., Moysich, K. B., Ness, R. B., Kjaer, S. K., Jensen, A., Schildkraut, J. M., Titus, L. J., Cramer, D. W., ... Terry, K. L. (2020). Association Between Breastfeeding and Ovarian Cancer Risk. *JAMA oncology*, 6(6), e200421. <https://doi.org/10.1001/jamaoncol.2020.0421>
- Bai, M., Li, Y., Pu, H., Xu, Y., Chen, J., Xu, H., ... & Feng, J. (2024). Optimal peritoneal cancer index cutoff point for predicting surgical resectability of pseudomyxoma peritonei in treatment-naïve patients. *World Journal of Surgical Oncology*, 22(1). <https://doi.org/10.1186/s12957-024-03318-4>
- Bandera, E. V., Lee, V. S., Rodriguez-Rodriguez, L., Powell, C. B., & Kushi, L. H. (2016). Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 22(23), 5909–5914. <https://doi.org/10.1158/1078-0432.CCR-16-1119>
- Bast, R.C., et al. (2005). CA 125: the past and the future. *Int J Biol Markers*, 20(1), 1–10.
- Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 143 Suppl 2, 59–78. <https://doi.org/10.1002/ijgo.12614>
- Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021). Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 155 Suppl 1(Suppl 1), 61–85. <https://doi.org/10.1002/ijgo.13878>
- Bergamini, A., Candiani, M., Taccagni, G., Rabaiotti, E., Viganò, R., De Marzi, P., Ferrari, D., & Mangili, G. (2016). Different Patterns of Disease Spread between Advanced-Stage Type I and II Epithelial Ovarian Cancer. *Gynecologic and obstetric investigation*, 81(1), 10–14. <https://doi.org/10.1159/000381261>
- Borges, S., et al. (2024) 'Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX model: Portuguese multicenter study', *Ultrasound in Obstetrics & Gynecology*. doi: 10.1002/uog.27641.

- Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. *Br J Cancer*. 2011;105(12):1818-24.
- Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol*, 20:1248-59. 10.1200/JCO.2002.20.5.1248
- Chang, L. C., Huang, C. F., Lai, M. S., Shen, L. J., Wu, F. L., & Cheng, W. F. (2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PloS one*, 13(3), e0194993. <https://doi.org/10.1371/journal.pone.0194993>
- Chen, H., Qian, L., Jiang, M., Du, Q., Yuan, F., & Feng, W. (2019). Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 54(6), 815–822. <https://doi.org/10.1002/uog.20363>
- Cherukuri, S., Jajoo, S., & Dewani, D. (2022). The International Ovarian Tumor Analysis-Assessment of Different Neoplasias in the Adnexa (IOTA-ADNEX) Model Assessment for Risk of Ovarian Malignancy in Adnexal Masses. *Cureus*, 14(11), e31194. <https://doi.org/10.7759/cureus.31194>
- Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma? *Gynecol Oncol*. 2006;103(2):559–64.
- Demirtaş, G. & Gökçü, M. (2021). The prognostic factors of survival and recurrence in patients with serous ovarian and uterine cancers treated in a single institution for 17 years. *Current Gynecologic Oncology*, 19(1), e8-e15. <https://doi.org/10.15557/cgo.2021.0002>
- Esquivel, R., Rodríguez, N., Ayala, N., Buriticá, C., Gómez, A., Velandia, A., ... & Alcázar, J. (2021). Two-Step Strategy for Optimizing the Preoperative Classification of Adnexal Masses in a University Hospital, Using International Ovarian Tumor Analysis Models. *Journal of Ultrasound in Medicine*, 41(2), 471-482. <https://doi.org/10.1002/jum.15728>
- Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. *Ann Surg Oncol*. 2006;13(8):1156-1161. doi:10.1245/ASO.2006.08.021.
- Forstner, R. (2021). Imaging of Ovarian Cancer: From Early Detection to Post-treatment Relapse. *EMJ Radiology*. <https://doi.org/10.33590/emjradiol/21-00086>
- Fotopoulou C, Concin N, Planchamp F, Morice P, Vergote I, du Bois A, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. *Int J Gynecol Cancer*. 2020;30(4):436-40. doi:10.1136/ijgc-2020-001248.

- Froyman W, Landolfo C, De Cock B, et al. Risk of complications in patients with adnexal masses classified using the ADNEX model. *Ultrasound Obstet Gynecol.* 2019;54(4):519–526.
- Gaitskell, K., Green, J., Pirie, K., Barnes, I., Hermon, C., Reeves, G. K., Beral, V., & Million Women Study Collaborators. (2018). Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. *International journal of cancer*, 142(2), 281–289. <https://doi.org/10.1002/ijc.31063>
- Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., Beral, V., Reeves, G. K., & Million Women Study Collaborators (2022). Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. *Cancer epidemiology*, 76, 102074. <https://doi.org/10.1016/j.canep.2021.102074>
- Gareeballah, A., Gameraddin, M., Alshoabi, S., Alsaedi, A., Elzaki, M., Alsharif, W., ... & Adam, M. (2025). The diagnostic performance of International Ovarian Tumor Analysis: Simple Rules for diagnosing ovarian tumors—a systematic review and meta-analysis. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1474930>
- Giourga, M., Pouliakis, A., Vlastarakos, P., Stavrou, S., Tsiriva, M., Gerede, A., Daskalakis, G., Voros, C., Drakakis, P., & Domali, E. (2023). Evaluation of IOTA-ADNEX Model and Simple Rules for Identifying Adnexal Masses by Operators with Varying Levels of Expertise: A Single-Center Diagnostic Accuracy Study. *Ultrasound international open*, 9(1), E11–E17. <https://doi.org/10.1055/a-2044-2855>
- Guo, Y., Zhao, B., Zhou, S., Wen, L., Liu, J., Fu, Y., Xu, F., & Liu, M. (2022). A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior doctors. *Ultrasonography (Seoul, Korea)*, 41(3), 511–518. <https://doi.org/10.14366/usg.21237>
- Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutr J.* 2010;9:69.
- Han WK, Wakabayashi H. Laparoscopy-based evaluation of peritoneal dissemination and prediction of surgical outcome in ovarian cancer. *J Gynecol Oncol.* 2011;22(4):256–261.
- Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ.* 2020;371:m4087. doi:10.1136/bmj.m4087.
- He, P., Wang, J. J., Duan, W., Song, C., Yang, Y., & Wu, Q. Q. (2021). Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China. *Journal of ovarian research*, 14(1), 169. <https://doi.org/10.1186/s13048-021-00922-w>
- Hidalgo, J. J., et al. (2020) 'Comparison of IOTA three-step strategy and logistic regression model LR2 for discriminating between benign and malignant adnexal masses', *Medical Ultrasonography*. doi: 10.11152/mu-2732.
- Iida, H., Kaibori, M., Matsui, K., Ishizaki, M., & Kon, M. (2016). Assessing the feasibility of clinicopathological features of hepatic resection for

- hepatocellular carcinoma in patients over 80 years of age. *Molecular and Clinical Oncology*, 6(1), 29-38. <https://doi.org/10.3892/mco.2016.1079>
- Inci MG, Wefers C, Becker G, et al. Frailty Index for prediction of surgical outcome in ovarian cancer: results of a prospective study. *Gynecol Oncol*. 2021.
- Iwasaki, M., Ishikawa, M., Namizato, D., & Sakamoto, A. (2022). Worse ECOG-PS Is Associated with Increased 30-Day Mortality among Adults Older than 90 Years Undergoing Non-Cardiac Surgery: A Single-Center Retrospective Study. *Journal of Nippon Medical School*, 89(3), 295-300. https://doi.org/10.1272/jnms.jnms.2022_89-304
- Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J Clin*. 2011;61(3):183-203. doi:10.3322/caac.20113.
- Jeong, S. Y., Park, B. K., Lee, Y. Y., & Kim, T. J. (2020). Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. *Journal of clinical medicine*, 9(6), 2010. <https://doi.org/10.3390/jcm9062010>
- Johnson, D., Riggs, S., Nielsen, M., Matthews, J., Woods, M., Wallen, E., ... & Smith, A. (2014). Nutritional predictors of complications following radical cystectomy. *World Journal of Urology*, 33(8), 1129-1137. <https://doi.org/10.1007/s00345-014-1409-z>
- Kachuri, Linda & Graff, Rebecca & Smith-Byrne, Karl & Meyers, Travis & Rashkin, Sara & Ziv, Elad & Witte, John & Johansson, Mattias. (2020). Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. *Nature Communications*. 11. 10.1038/s41467-020-19600-4.
- Kang, E., Park, H., Lee, J., Kim, H., Noh, W., Jung, Y., ... & Kim, S. (2016). KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients. *Journal of Human Genetics*, 61(5), 365-371. <https://doi.org/10.1038/jhg.2015.164>
- Khalafi-Nezhad, A., Ebrahimi, V., Ahmadpour, F., Momtahan, M., Robati, M., Saraf, Z., Ramzi, M., Jowkar, Z., & Ghaffari, P. (2020). Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer. *Cancer management and research*, 12, 1447–1456. <https://doi.org/10.2147/CMAR.S237073>
- Karisma MN, Budiana ING, Mahendra INB, Putra IGM, Surya IGNHW, Putra IWA. Accuracy of cancer antigen 125 and albumin before operation to predict the operation outcome in patients with advanced stage epithelial type ovarian cancer. *Syntax Health Sains*. 2023;4(5):86-96.
- Kim SJ, Rosen B, Fan I, et al. (2017). Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *Br J Cancer*;116(7):964. doi:10.1038/bjc.2017.35
- Kobal, B., Rakar, S., Ribič-Pucelj, M., Tomažević, T., & Zaletel-Kragelj, L. (1999). Pretreatment evaluation of adnexal tumors predicting ovarian cancer. *International Journal of Gynecological Cancer*, 9(6), 481-486. <https://doi.org/10.1046/j.1525-1438.1999.99057.x>

- Köbel, M., & Kang, E. Y. (2022). The Evolution of Ovarian Carcinoma Subclassification. *Cancers*, 14(2), 416. <https://doi.org/10.3390/cancers14020416>
- Koirala, P., Moon, A., & Chuang, L. (2020). Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. *Diagnostics*, 10(8), 568. <https://doi.org/10.3390/diagnostics10080568>
- Kovács, A., Sulina, A., Kovács, K., Lukács, L., Török, P., & Lampé, R. (2023). Prognostic Significance of Preoperative NLR, MLR, and PLR Values in Predicting the Outcome of Primary Cytoreductive Surgery in Serous Epithelial Ovarian Cancer. *Diagnostics*, 13(13), 2268. <https://doi.org/10.3390/diagnostics13132268>
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al; BRCA1 and BRCA2 Cohort Consortium. Association of BRCA1 and BRCA2 mutation carrier status with risks of breast, ovarian, and contralateral breast cancer. *JAMA*. 2017;317(23):2402-16. doi:10.1001/jama.2017.7112.
- Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis. *Am J Pathol*. 2016;186(4):733–747.
- Ledermann, J. A., Luvero, D., Shafer, A., O'Connor, D., Mangili, G., Friedlander, M., Pfisterer, J., Mirza, M. R., Kim, J. W., Alexandre, J., Oza, A., & Brown, J. (2014). Gynecologic Cancer InterGroup (GCIg) consensus review for mucinous ovarian carcinoma. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 24(9 Suppl 3), S14–S19. <https://doi.org/10.1097/IGC.0000000000000296>
- Leitzmann MF, Koebnick C, Danforth KN, et al. (2009). Body mass index and risk of ovarian cancer. *Cancer*;115(4):812–822. doi:10.1002/cncr.24086
- Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of sample size in health studies. Chichester: John Wiley & Sons; 1990.
- Lim, A., Mesher, D., Gentry-Maharaj, A., Balogun, N., Widschwendter, M., Jacobs, I., Sasieni, P., & Menon, U. (2016). Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. *BJOG : an international journal of obstetrics and gynaecology*, 123(6), 1012–1020. <https://doi.org/10.1111/1471-0528.13447>
- Liu Y, Chen X, Zhang J, Gao Y, Wang Y. Impact of body mass index on surgical and oncological outcomes in patients with ovarian cancer: a systematic review and meta-analysis. *J Ovarian Res*. 2019;12(1):1–10.
- Lynch, H. T., Snyder, C., & Casey, M. J. (2013). Hereditary ovarian and breast cancer: what have we learned?. *Annals of oncology : official journal of the European Society for Medical Oncology*, 24 Suppl 8, viii83–viii95. <https://doi.org/10.1093/annonc/mdt313>
- Macrì, A., Accarpio, F., Arcoraci, V., Casella, F., Cian, F., Iaco, P., ... & Galati, M. (2020). Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study. *Pleura and Peritoneum*, 6(1), 21-30. <https://doi.org/10.1515/pp-2020-0139>

- Makker, P., Koh, C., Ansari, N., Gonzaga, N., Bartyn, J., Solomon, M., ... & Steffens, D. (2022). Functional Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Cohort Study. *Annals of Surgical Oncology*, 30(1), 447-458. <https://doi.org/10.1245/s10434-022-12691-x>
- Mallen, A., Soong, T. R., Townsend, M. K., Wenham, R. M., Crum, C. P., & Tworoger, S. S. (2018). Surgical prevention strategies in ovarian cancer. *Gynecologic oncology*, 151(1), 166-175. <https://doi.org/10.1016/j.ygyno.2018.08.005>
- Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Karpinskyj C, Gunu R, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*. 2021;397(10290):2182-93.
- Mohan, L., Rao, A., Ullal, S., & Krishna, G. (2016). Accuracy of Pelvic Mass Score in Pre-operative Determination of Malignancy in Adnexal Masses. *Journal of clinical and diagnostic research : JCDR*, 10(11), QC01-QC03. <https://doi.org/10.7860/JCDR/2016/20686.8867>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: epidemiology and risk factors. *International journal of women's health*, 11, 287-299. <https://doi.org/10.2147/IJWH.S197604>
- Monk BJ, Chan JK. (2017). Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?. *Ann Oncol*, 28:viii40-5. 10.1093/annonc/mdx451
- Morice, P., Gouy, S., & Leary, A. (2019). Mucinous Ovarian Carcinoma. *The New England journal of medicine*, 380(13), 1256-1266. <https://doi.org/10.1056/NEJMra1813254>
- Nagle CM, Dixon SC, Jensen A, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *Br J Cancer*. 2015;113(5):817-826.
- Nash, Z., & Menon, U. (2020). Ovarian cancer screening: Current status and future directions. *Best practice & research. Clinical obstetrics & gynaecology*, 65, 32-45. <https://doi.org/10.1016/j.bpobgyn.2020.02.010>
- Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol*. 2016;2(4):482-490.
- PDQ Adult Treatment Editorial Board. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®): health professional version. In: *PDQ Cancer Information Summaries* [Internet]. Bethesda (MD): National Cancer Institute (US); 2023.
- Piedimonte, S., Bernardini, M., Ding, A., Laframboise, S., Ferguson, S., Bouchard-Fortier, G., ... & Hogen, L. (2023). Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer. *International Journal of Gynecological Cancer*, 33(7), 1077-1082. <https://doi.org/10.1136/ijgc-2022-004202>
- Poonyakanok, V., Tanmahasamut, P., & Jaishuen, A. (2023). Prospective comparative trial comparing O-RADS, IOTA ADNEX model, and RMI

- score for preoperative evaluation of adnexal masses for prediction of ovarian cancer. *Journal of Obstetrics and Gynaecology Research*, 49(5), 1412-1417. <https://doi.org/10.1111/jog.15624>
- Ray S, et al. Diagnostic accuracy of the risk of malignancy index 1 compared to the more recent IOTA ADNEX model in discriminating benign from malignant adnexal masses: a multi-centric study. *Int J Reprod Contracept Obstet Gynecol*. 2019. doi:10.18203/2320-1770.ijrcog20190871.
- Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. *Cancer biology & medicine*, 14(1), 9–32. <https://doi.org/10.20892/j.issn.2095-3941.2016.0084>
- Risch HA, Marrett LD, Jain M, Howe GR. (1996). Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. *Am J Epidemiol*;144(4):363–372.
- Rousseau, F., Ranchon, F., Bardin, C., Bakrin, N., Lavoué, V., Bengrine-Lefevre, L., ... & Falandry, C. (2023). Ovarian cancer in the older patient: where are we now? What to do next?. *Therapeutic Advances in Medical Oncology*, 15. <https://doi.org/10.1177/17588359231192397>
- Sayasneh, A., et al. (2013) 'Multicentre external validation of IOTA prediction models and RMI by operators with varied training', *British Journal of Cancer*, 108(12), pp. 2448-2454. doi: 10.1038/bjc.2013.224.
- Schrijver, L. H., Antoniou, A. C., Olsson, H., Mooij, T. M., Roos-Blom, M. J., Azarang, L., Adlard, J., Ahmed, M., Barrowdale, D., Davidson, R., Donaldson, A., Eeles, R., Evans, D. G., Frost, D., Henderson, A., Izatt, L., Ong, K. R., Bonadona, V., Coupier, I., Faivre, L. (2021). Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. *American journal of obstetrics and gynecology*, 225(1), 51.e1–51.e17. <https://doi.org/10.1016/j.ajog.2021.01.014>
- Seebacher, V., Aust, S., D'Andrea, D., Grimm, C., Reiser, E., Tiringier, D., ... & Helmy-Bader, S. (2017). Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. *PLoS One*, 12(8), e0182383. <https://doi.org/10.1371/journal.pone.0182383>
- SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Accessed at <https://seer.cancer.gov/explorer/> on February 23, 2023.
- Shapiro, C., Phillips, G., Poznak, C., Jackson, R., LeBoff, M., Woodard, S., ... & Lemeshow, S. (2005). Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. *Breast Cancer Research and Treatment*, 90(1), 41-46. <https://doi.org/10.1007/s10549-004-2625-9>
- Siegel RL, Miller KD, Jemal A. Cancer statistics. (2020). *CA Cancer J Clin*. 2020 Jan;70(1):7-30.

- Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. *CA: a cancer journal for clinicians*, 73(1), 17–48. <https://doi.org/10.3322/caac.21763>
- Sladkevicius, P. and Valentin, L. (2015) 'Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models', *Clinical Cancer Research*, 21(3), pp. 594-601. doi: 10.1158/1078-0432.CCR-14-0906.
- Solanki, V., Singh, P., Sharma, C., Ghuman, N., Sureka, B., Shekhar, S., Gothwal, M., & Yadav, G. (2020). Predicting Malignancy in Adnexal Masses by the International Ovarian Tumor Analysis-Simple Rules. *Journal of mid-life health*, 11(4), 217–223. https://doi.org/10.4103/jmh.JMH_103_20
- Stewart, C., Ralyea, C., & Lockwood, S. (2019). Ovarian Cancer: An Integrated Review. *Seminars in oncology nursing*, 35(2), 151–156. <https://doi.org/10.1016/j.soncn.2019.02.001>
- Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol*. 2014;134(3):455-61.
- Testa AC, Ferrandina G, Fruscella E, Van Holsbeke C, Ludovisi M, Mascilini F, et al. Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study. *Ultrasound Obstet Gynecol*. 2012;39(1):99-105.
- Testa, A. C., et al. (2014) 'Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study', *British Journal of Cancer*, 111(4), pp. 680-688. doi: 10.1038/bjc.2014.333.
- Timmerman, D., et al. (2005) 'Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group', *Journal of Clinical Oncology*, 23(34), pp. 8794-8801. doi: 10.1200/JCO.2005.01.7632.
- Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer: IOTA group overview. *Ultrasound Obstet Gynecol*. 2016;48(1):1–10.
- Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L., Cibula, D., Concin, N., Fischerova, D., Froyman, W., Gallardo Madueño, G., Lemley, B., Loft, A., Mereu, L., Morice, P., Querleu, D., Testa, A. C., Vergote, I., Vandecaveye, V., Scambia, G., Fotopoulou, C. (2021). ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, 31(7), 961–982. <https://doi.org/10.1136/ijgc-2021-002565>
- Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018). Ovarian cancer statistics, 2018. *CA: a cancer journal for clinicians*, 68(4), 284–296. <https://doi.org/10.3322/caac.21456>

- Trabert, B., Tworoger, S. S., O'Brien, K. M., Townsend, M. K., Fortner, R. T., Iversen, E. S., Hartge, P., White, E., Amiano, P., Arslan, A. A., Bernstein, L., Brinton, L. A., Buring, J. E., Dossus, L., Fraser, G. E., Gaudet, M. M., Giles, G. G., Gram, I. T., Harris, H. R., Bolton, J. H., ... Ovarian Cancer Cohort Consortium (OC3) (2020). The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). *Cancer research*, 80(5), 1210–1218. <https://doi.org/10.1158/0008-5472.CAN-19-2850>
- Trimbos JB, Vergote I, Bolis G, et al. (2003). Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. *J Natl Cancer Inst*, 95:113-25.
- Tschernichovsky, R., & Goodman, A. (2017). Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. *The oncologist*, 22(4), 450–459. <https://doi.org/10.1634/theoncologist.2016-0444>
- Van Calster, B., et al. (2012) 'Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol', *BJOG: An International Journal of Obstetrics & Gynaecology*, 119(6), pp. 662-671. doi: 10.1111/j.1471-0528.2012.03297.x.
- Van Calster, B., Valentin, L., Froyman, W., Landolfo, C., Ceusters, J., Testa, A. C., Wynants, L., Sladkevicius, P., Van Holsbeke, C., Domali, E., Fruscio, R., Epstein, E., Franchi, D., Kudla, M. J., Chiappa, V., Alcazar, J. L., Leone, F. P. G., Buonomo, F., Coccia, M. E., Guerriero, S., Timmerman, D. (2020). Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. *BMJ (Clinical research ed.)*, 370, m2614. <https://doi.org/10.1136/bmj.m2614>
- Van Calster, B., Van Hoorde, K., Froyman, W., Kaijser, J., Wynants, L., Landolfo, C., Anthoulakis, C., Vergote, I., Bourne, T., & Timmerman, D. (2015). Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. *Facts, views & vision in ObGyn*, 7(1), 32–41.
- Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, et al. Predicting the risk of malignancy in adnexal masses based on the ADNEX model: development and multicentre validation study. *BMJ*. 2014;349:g5920.
- Velayo, C., et al. (2022) 'Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses', *Healthcare*, 11(1), p. 8. doi: 10.3390/healthcare11010008.
- Vergote I, Coens C, Nankivell M, et al. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. *Lancet Oncol*, 19:1680-7. 10.1016/S1470-2045(18)30566-7
- Viora, E., Piovano, E., Baima Poma, C., Cotrino, I., Castiglione, A., Cavallero, C., Sciarrone, A., Bastonero, S., Iskra, L., & Zola, P. (2020). The ADNEX

- model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator. *European journal of obstetrics, gynecology, and reproductive biology*, 247, 207–211. <https://doi.org/10.1016/j.ejogrb.2020.02.022>
- Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. Effect of obesity on perioperative outcomes in women undergoing gynecologic cancer surgery. *Obstet Gynecol*. 2012;120(3):589–96.
- Wynants L, Timmerman D, Verbakel JY, Testa AC, Van Holsbeke C, Bourne T, et al. Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis. *Clin Cancer Res*. 2017;23(17):5082–5090. doi:10.1158/1078-0432.CCR-16-1804. *Ultrasound Obstet Gynecol*. 2017;50(1):20–28. doi:10.1002/uog.17388
- Xi, S., Li, Z., Guo, Q., Lin, W., Liang, X., & Ma, L. (2020). Prognostic Factors among Brain Metastases in Newly Diagnosed Ovary Cancer: A Large Real-world Study. *Journal of Cancer*, 11(15), 4625-4640. <https://doi.org/10.7150/jca.44494>
- Xia, Y. Y., Gronwald, J., Karlan, B., Lubinski, J., McCuaig, J. M., Brooks, J., Moller, P., Eisen, A., Sun, S., Senter, L., Bordeleau, L., Neuhausen, S. L., Singer, C. F., Tung, N., Foulkes, W. D., Sun, P., Narod, S. A., Kotsopoulos, J., & Hereditary Ovarian Cancer Clinical Study Group. (2022). Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Gynecologic oncology*, 164(3), 514–521. <https://doi.org/10.1016/j.ygyno.2022.01.014>
- Xie, F., Yang, H., Wang, S., Zhou, B., Tong, F., Yang, D., ... & Zhang, J. (2012). A Logistic Regression Model for Predicting Axillary Lymph Node Metastases in Early Breast Carcinoma Patients. *Sensors*, 12(7), 9936-9950. <https://doi.org/10.3390/s120709936>
- Yang Y, et al. Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer. *Front Oncol*. 2022. doi:10.3389/fonc.2022.949766.
- Zamwar, U. M., & Anjankar, A. P. (2022). Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. *Cureus*, 14(10), e30561. <https://doi.org/10.7759/cureus.30561>
- Zhang, W., Zhang, W., Lin, Z., Wang, F., Li, M., Zhu, L., ... & Gao, Y. (2019). Survival Outcomes of Patients with Primary Breast Cancer Following Primary Ovarian Cancer. *Medical Science Monitor*, 25, 3869-3879. <https://doi.org/10.12659/msm.914163>
- Zhao, H., Xu, F., Li, J., Ni, M., & Wu, X. (2020). A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.571671>
- Žilovič, D., Čiurlienė, R., Sabaliauskaitė, R., & Jarmalaitė, S. (2021). Future Screening Prospects for Ovarian Cancer. *Cancers*, 13(15), 3840. <https://doi.org/10.3390/cancers13153840>